Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZR-MTX Regimen in Primary Intraocular Lymphoma
NCT06973811Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in primary intraocular lymphoma (PIOL), sponsored by Peking Union Medical College Hospital. Started Oct 2024; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
primary intraocular lymphoma (PIOL)
Beyond the preview
Go deeper on NCT06973811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06973811.